Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus DYNAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus DYNAPEN.
CLOXAPEN vs DYNAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic